Search
Clesrovimab
go.drugbank.com/drugs/DB18877Approved[A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalIt was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. … Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca.
Categories: Compounds used in a research, industrial, or household setting, Drugs for ConstipationPoliovirus type 2 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10796ApprovedInvestigationalPoliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Polio Salk "Merieux" - FertigspritzeSynonyms: Inactivated poliovirus type IIRilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Categories: Receptors, Interleukin-1 Type ISynonyms: IL-1 TRAP, IL-1-TRAPFenoldopam
go.drugbank.com/drugs/DB00800ApprovedA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Categories: Antihypertensive Agents Indicated for HypertensionZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigational[L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan. … The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383]
Categories: Compounds used in a research, industrial, or household setting, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesVamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … option in patients for whom corticosteroid adverse effects are intolerable or otherwise unacceptable.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainMangafodipir
go.drugbank.com/drugs/DB06796ApprovedInvestigationalWithdrawnManganese absorption into the tissues that makes the normal tissue appear brighter in MRI is limited in abnormal or cancerous tissue. … Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas.
Categories: Compounds used in a research, industrial, or household settingAcemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigationalit kept the same side effects. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSProducts: RASLACOF-XRamelteon
go.drugbank.com/drugs/DB00980ApprovedInvestigationalIt is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. … Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN).